The UPS: a promising target for breast cancer treatment.
The UPS: a promising target for breast cancer treatment.
复制标题
DOI：
10.1186/1471-2091-9-s1-s2
复制
发表时间：
2008-10-21
期刊：
影响因子：
--
通讯作者：
Ohta T
中科院分区：
文献类型：
--
作者：
Sato K;Rajendra E;Ohta T
在过去十年中，内分泌治疗的进展和曲妥珠单抗的使用分别显著降低了激素受体阳性和ERBB 2（HER 2）阳性病例的乳腺癌死亡率。作为这些进展的结果，具有不良预后的乳腺癌集群（其对雌激素受体（ESR 1）、孕激素受体（PRGR）和ERBB 2（三阴性）呈阴性）已经成为医学治疗关注的前沿。DNA微阵列分析显示，这一簇在表型上最像是由BRCA 1通路缺陷引起的基底样乳腺癌。为了进一步提高乳腺癌的生存率，可能需要新型药物，靶向泛素蛋白酶体系统的小分子已经成为人们关注的焦点。硼替佐米治疗多发性骨髓瘤的成功发出了令人鼓舞的信号，即蛋白酶体抑制剂可用于治疗其他类型的癌症。此外，参与ESR 1、ERBB 2或BRCA 1通路的泛素E3可能是治疗干预的理想靶点。本文综述了与这些蛋白质相关的泛素蛋白酶体通路，并讨论了乳腺癌治疗新药的可能性。从Current BioData的靶向蛋白质数据库（TPdb;）重新发布。
During the past decade, progress in endocrine therapy and the use of trastuzumab has significantly contributed to the decline in breast cancer mortality for hormone receptor-positive and ERBB2 (HER2)-positive cases, respectively. As a result of these advances, a breast cancer cluster with poor prognosis that is negative for the estrogen receptor (ESR1), the progesterone receptor (PRGR) and ERBB2 (triple negative) has come to the forefront of medical therapeutic attention. DNA microarray analyses have revealed that this cluster is phenotypically most like the basal-like breast cancer that is caused by deficiencies in the BRCA1 pathways. To gain further improvements in breast cancer survival, new types of drugs might be required, and small molecules targeting the ubiquitin proteasome system have moved into the spotlight. The success of bortezomib in the treatment of multiple myeloma has sent encouraging signals that proteasome inhibitors could be used to treat other types of cancers. In addition, ubiquitin E3s involved in ESR1, ERBB2 or BRCA1 pathways could be ideal targets for therapeutic intervention. This review summarizes the ubiquitin proteasome pathways related to these proteins and discusses the possibility of new drugs for the treatment of breast cancers. Republished from Current BioData's Targeted Proteins database (TPdb; ).